Why Daily Baby Moisturizer Did Not Prevent Eczema in Large Trials

Two large, well-conducted randomized trials set out to prove a tidy idea, that rubbing moisturizer into a baby's skin every day from birth would head off eczema before it started, and both failed at the endpoint that mattered. In the United Kingdom, the BEEP trial found that daily emollient through the first year did not lower the rate of eczema at age two, and in Norway and Sweden the PreventADALL trial found no reduction in atopic dermatitis by twelve months. Worse, the moisturized infants in BEEP had measurably more skin infections. A biologically plausible barrier-repair hypothesis, backed by encouraging pilot data, did not survive contact with adequately powered confirmatory trials.

Why the hypothesis looked so convincing

Eczema, or atopic dermatitis, usually begins in the first months of life, and one of its earliest features is a leaky epidermal barrier. Children who carry loss-of-function variants in the filaggrin gene, which helps build that barrier, have a substantially higher risk of eczema. A wider model followed: if a defective barrier lets water escape and lets allergens and irritants in, then early sensitization and the later atopic march toward food allergy and asthma might all trace back to the skin. Restore the barrier early with emollient, the reasoning went, and you might interrupt the whole cascade.

Two small pilot trials published in 2014, one in the US and UK and one in Japan, each enrolling around 120 high-risk infants, reported that daily emollient roughly halved eczema incidence in the first months. Those signals were genuinely exciting, and they justified the expense of large confirmatory trials. That is exactly how the evidence pipeline is supposed to work.

What the large trials tested

BEEP randomized 1,394 newborns with a family history of atopic disease to either daily whole-body emollient for the first year plus standard skin-care advice, or standard advice alone. Its primary outcome was clinically assessed eczema at age two, using validated UK Working Party criteria. PreventADALL took a broader, general-population sample of 2,397 infants in a factorial design, assigning a skin regimen (emollient bath additives plus facial cream, applied at least four days a week from two weeks of age) with or without early introduction of allergenic foods. Its primary outcome was atopic dermatitis by twelve months.

The result was no prevention

The effect on eczema was flat. In BEEP, eczema was present in 23% of the emollient group versus 25% of controls, an adjusted relative risk of 0.95 (95% CI 0.78 to 1.16, p=0.61). In PreventADALL, atopic dermatitis occurred in 11% of the skin-intervention group versus 8% of the no-intervention group, a risk difference of 3.1% (95% CI -0.3 to 6.5) that pointed, if anything, slightly toward the control side. Follow-up did not rescue the idea. The BEEP five-year results, reported in 2023, found no protection against eczema, food allergy, asthma, or hay fever through age five.

The safety signals ran the wrong way

A neutral efficacy result is disappointing; a neutral result paired with a hint of harm is disqualifying for a preventive strategy. In BEEP, children in the emollient group averaged more skin infections in the first year (adjusted incidence rate ratio 1.55, 95% CI 1.15 to 2.09). A 2022 Cochrane systematic review and meta-analysis, pooling data across dozens of trials, reached the same verdict with more precision: skin-care interventions in infancy probably do not change the risk of eczema (risk ratio 1.03, 95% CI 0.81 to 1.31), probably increase skin infections (risk ratio 1.33, 95% CI 1.01 to 1.75), and may increase IgE-mediated food allergy. The benefit did not appear even in infants carrying filaggrin mutations, the very subgroup the mechanism predicted should gain the most. PreventADALL, by contrast, did not report a comparable increase in skin infections, so the infection signal is not uniform across every protocol, but the efficacy conclusion is.

What the reversal teaches about reading evidence

This is a clean case study in why mechanism and early signals are not the same as proof. Three lessons stand out. First, a small efficacy signal in an underpowered pilot often shrinks toward zero once a trial is large enough to measure it honestly; regression toward the null is closer to the rule than the exception. Second, improving a measurable surrogate, in this case the skin barrier and its hydration, does not guarantee a change in the clinical diagnosis families actually care about. Third, prevention has to clear a higher bar than treatment, because a healthy population is being exposed, so even a modest harm signal such as added infections tips the balance against routine use.

The trialists themselves, and later guideline reviews, concluded that daily emollient should not be recommended to prevent eczema in newborns, whether or not the family carries a high atopic risk. Ordinary gentle skin care for a comfortable baby remains reasonable; using moisturizer as if it were a preventive drug does not hold up. This article is educational and is not medical advice, and decisions about an individual infant's skin belong with that family and their clinician.